Guggenheim started coverage on shares of Mylan (NASDAQ:MYL) in a research note published on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $59.00 price target on the stock.

MYL has been the topic of several other reports. Cowen restated a market perform rating and issued a $36.00 price target (up from $30.00) on shares of Mylan in a research note on Thursday, October 5th. Mizuho restated a buy rating and issued a $37.00 price target on shares of Mylan in a research note on Tuesday, October 24th. Zacks Investment Research downgraded shares of Mylan from a buy rating to a hold rating in a research note on Wednesday, November 8th. UBS set a $46.00 price target on shares of Mylan and gave the company a buy rating in a research note on Monday, December 4th. Finally, Citigroup set a $42.00 price target on shares of Mylan and gave the company a buy rating in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $42.41.

Mylan (NASDAQ MYL) opened at $40.52 on Tuesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. Mylan has a 1 year low of $29.39 and a 1 year high of $45.87. The firm has a market cap of $21,462.81, a PE ratio of 8.51, a PEG ratio of 2.19 and a beta of 1.38.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan had a net margin of 7.28% and a return on equity of 20.63%. The business had revenue of $2.99 billion during the quarter, compared to analyst estimates of $3.09 billion. During the same quarter last year, the company posted $1.38 earnings per share. The company’s revenue was down 2.3% on a year-over-year basis. sell-side analysts predict that Mylan will post 4.56 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its holdings in Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares during the last quarter. BT Investment Management Ltd bought a new position in Mylan in the 3rd quarter valued at approximately $142,000. Global X Management Co. LLC raised its holdings in Mylan by 59.2% in the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after buying an additional 1,786 shares during the last quarter. Doliver Capital Advisors LP bought a new position in Mylan in the 2nd quarter valued at approximately $201,000. Finally, Sheaff Brock Investment Advisors LLC bought a new position in Mylan in the 2nd quarter valued at approximately $210,000. Institutional investors own 75.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Guggenheim Initiates Coverage on Mylan (MYL)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/16/guggenheim-initiates-coverage-on-mylan-myl.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.